Phenotypic correction of Fanconi anemia cells in the murine bone marrow after carrier cell mediated delivery of lentiviral vector

[1]  J. Soulier,et al.  Biallelic inactivation of REV7 is associated with Fanconi anemia. , 2016, The Journal of clinical investigation.

[2]  Xiaonan Dong,et al.  Fanconi Anemia Proteins Function in Mitophagy and Immunity , 2016, Cell.

[3]  J. Soulier,et al.  TGF-β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. , 2016, Cell stem cell.

[4]  K. Kasow,et al.  Sequential renal and bone marrow transplants in a child with Fanconi anemia , 2016, Pediatric transplantation.

[5]  J. Walter,et al.  What is the DNA repair defect underlying Fanconi anemia? , 2015, Current opinion in cell biology.

[6]  C. von Kalle,et al.  Lentiviral-Mediated Gene Therapy in Fanconi Anemia-A Mice Reveals Long-Term Engraftment and Continuous Turnover of Corrected HSCs. , 2015, Current gene therapy.

[7]  Atique U. Ahmed,et al.  Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions , 2015, Viruses.

[8]  J. Surrallés,et al.  Activation of the Fanconi anemia/BRCA pathway at low doses of ionization radiation. , 2015, Mutation research. Genetic toxicology and environmental mutagenesis.

[9]  Q. Xu,et al.  A Successful Second Stem Cell Transplantation in Fanconi Anemia: A Case Report. , 2015, Transplantation proceedings.

[10]  Amelie Lier,et al.  The Fanconi anemia pathway is required for efficient repair of stress-induced DNA damage in haematopoietic stem cells , 2015, Cell cycle.

[11]  D. Rawlings,et al.  Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  CavazzanaMarina.  Hematopoietic stem cell gene therapy: progress on the clinical front. , 2014 .

[13]  P. Kurre,et al.  Cell- Cell Transmission of VSV-G Pseudotyped Lentivector Particles , 2013, PloS one.

[14]  P. Veys,et al.  Production and First-in-Man Use of T Cells Engineered to Express a HSVTK-CD34 Sort-Suicide Gene , 2013, PloS one.

[15]  David A. Williams,et al.  Overcoming reprogramming resistance of Fanconi anemia cells. , 2012, Blood.

[16]  S. Kato,et al.  Matched sibling donor stem cell transplantation for Fanconi anemia patients with T‐cell somatic mosaicism , 2012, Pediatric transplantation.

[17]  M. Capogrossi,et al.  The SDF-1/CXCR4 axis in stem cell preconditioning. , 2012, Cardiovascular research.

[18]  M. Buitenhuis,et al.  Molecular mechanisms underlying adhesion and migration of hematopoietic stem cells , 2012, Cell adhesion & migration.

[19]  P. Kurre,et al.  Entry kinetics and cell–cell transmission of surface‐bound retroviral vector particles , 2010, The journal of gene medicine.

[20]  M. Carreau,et al.  Correction of Fanconi Anemia Group C Hematopoietic Stem Cells Following Intrafemoral Gene Transfer , 2010, Anemia.

[21]  David A. Williams,et al.  Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia. , 2009, Mutation research.

[22]  L. Luo,et al.  A global double‐fluorescent Cre reporter mouse , 2007, Genesis.

[23]  A. Annoni,et al.  In vivo administration of lentiviral vectors triggers a type I interferon response that restricts hepatocyte gene transfer and promotes vector clearance. , 2007, Blood.

[24]  Megan Brown,et al.  Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. , 2007, Blood.

[25]  W. Greene,et al.  In Vitro Derived Dendritic Cells trans-Infect CD4 T Cells Primarily with Surface-Bound HIV-1 Virions , 2007, PLoS pathogens.

[26]  J. Dausset,et al.  In vivo repopulation ability of genetically corrected bone marrow cells from Fanconi anemia patients , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Segovia,et al.  A simplified approach to improve the efficiency and safety of ex vivo hematopoietic gene therapy in fanconi anemia patients. , 2006, Human gene therapy.

[28]  Atique U. Ahmed,et al.  Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells , 2005, Nature Medicine.

[29]  L. van Damme,et al.  Intravaginal and intrarectal microbicides to prevent HIV infection , 2005, Canadian Medical Association Journal.

[30]  J. Wagner,et al.  Somatic mosaicism in Fanconi anemia: Evidence of genotypic reversion in lymphohematopoietic stem cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Cavazzana.  Hematopoietic stem cell gene therapy: progress on the clinical front. , 2014, Human gene therapy.

[32]  R. Alon,et al.  Pathways implicated in stem cell migration: the SDF-1/CXCR4 axis. , 2011, Methods in molecular biology.

[33]  Olivier Gout,et al.  Biofilm-like extracellular viral assemblies mediate HTLV-1 cell-to-cell transmission at virological synapses , 2010, Nature Medicine.

[34]  S. Russell,et al.  Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  David A. Williams,et al.  Stem cell collection and gene transfer in Fanconi anemia. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  A. D’Andrea,et al.  Preclinical protocol for in vivo selection of hematopoietic stem cells corrected by gene therapy in Fanconi anemia group C. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  M. Buchwald,et al.  A functionally active retrovirus vector for gene therapy in Fanconi anemia group C. , 1994, Blood.